The Challenges of an HIV Vaccine Enterprise [2] (multiple letters)

Science

Volumn 303, Issue 5662, 2004, Pages 1294-1297

  Zinkernagel, Rolf M ^a   Wolf, Hans ^b   Klasner, Richard D ^c   Fauci, Anthony S ^d   Corey, Lawrence ^e   Nabel, Gary J ^d   Gayle, Helene ^c   Berkley, Seth ^f   Haynes, Barton F ^g   Baltimore, David ^h   Collins, Chris ⁱ   Douglas, R Gordon ^j   Esparza, Jose ^k   Francis, Donald P ^l   Ganguly, N K ^m   Gerberding, Julie Louise ⁿ   Johnson, Margaret I ^d   Kazatchkine, Michel D ^o   McMichael, Andrew J ^p   Makgoba, Malegapuru W ^q   Pantaleo, Giuseppe ^r   Piot, Peter ^k   Shao, Yiming ^s   Tramont, Edmund ^d   Varmus, Harold ^t   Wasserheit, Judith N ^e   more..

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

ⁱ AIDS Vaccine Advocacy Coalition   (United States)

^j Sequella Global TB Foundation   (United States)

^k UNAIDS   (Switzerland)

^l VaxGen Inc   (United States)

^m INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

ⁿ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^o Agence Natl de Rech Sur le SIDA   (France)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q UNIVERSITY OF KWAZULU NATAL   (South Africa)

^r LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^s CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; BCG VACCINE;

HUMAN IMMUNODEFICIENCY VIRUS;

BIOMEDICINE; CELLULAR IMMUNITY; DISEASE COURSE; DRUG INDUSTRY; DRUG RESEARCH; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; POLICY; PRIORITY JOURNAL; VACCINE PRODUCTION; HEALTH; IMMUNOLOGY; NOTE; PUBLIC HEALTH; TUBERCULOSIS; BIOTECHNOLOGY; CLINICAL TRIAL; ECONOMICS; FINANCIAL MANAGEMENT; INTERNATIONAL COOPERATION; MULTICENTER STUDY; ORGANIZATION; ORGANIZATION AND MANAGEMENT;

HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; BCG VACCINE; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; PUBLIC HEALTH; TUBERCULOSIS; WORLD HEALTH; ACADEMIES AND INSTITUTES; BIOTECHNOLOGY; CLINICAL TRIALS; INTERNATIONAL COOPERATION; MULTICENTER STUDIES; RESEARCH SUPPORT;

EID: 12144288296     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.303.5662.1294     Document Type: Letter

References (0)